LifeVantage Corporation

What they do

LifeVantage identifies, researches, formulates and sells nutrigenomic activators, dietary supplements, weight management, gut health, skin and hair care products, and nootropics. Products include Protandim, the MindBody GLP-1 System, the P84 System gut health activator, TrueScience skin care, Petandim for dogs, and AXIO nootropic and hydration drink mixes. The company sells through independent consultants in the U.S., Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand and several European countries, having transitioned from retail to direct sales in 2008.

Revenue drivers

• Protandim and LifeVantage supplement lines — Protandim is described as the flagship scientifically validated dietary supplement line, supported by LifeVantage-branded supplements including the MindBody GLP-1 System, Omega+, ProBio, IC Bright, Rise AM & Reset PM, D3+, Daily Wellness, Fat Burn, Prebiotic and Carb Block.
• P84 System and LoveBiome-acquired products — Following the October 2025 acquisition of LoveBiome's critical operating assets, the company launched the P84 System (PhytoPower 1 and 2), plus Carb Block, AXIO X and AXIO Hydrate; these launches partially offset the fourth quarter revenue decline.
• TrueScience skin and hair care — TrueScience is the skin and hair care line including Liquid Collagen; TrueRefine Glow-Up Mask was launched as a limited-time offering in fiscal 2026.
• Americas vs. Asia/Pacific & Europe geographic split — Fiscal 2026 revenue fell 23.2% in the Americas and 6.9% in Asia/Pacific & Europe, indicating the Americas is the larger and more challenged region by rate of decline.

Recent performance

Fiscal 2026 revenue was $182.6 million, a 20.1% decrease from fiscal 2025 revenue of $228.5 million. Fourth quarter fiscal 2026 revenue was $42.4 million, down 23.1% year over year, with Americas revenue down 24.8% and Asia/Pacific & Europe down 16.9%. Fiscal 2026 net income was $5.1 million, or $0.40 per diluted share, versus $9.8 million, or $0.75 per diluted share, in fiscal 2025. Fourth quarter gross margin was 78.0% versus 79.9% a year ago, pressured by product mix, inventory obsolescence and higher shipping costs. Fiscal 2026 adjusted EBITDA was $13.7 million compared to $22.1 million a year ago.

Strategy

Management states its early focus is on strengthening the LifeVantage brand, building a more relevant consumer proposition, and driving operational excellence. Fiscal 2026 product activity centered on integrating the October 2025 LoveBiome asset acquisition, launching the P84 System, Carb Block, AXIO X and AXIO Hydrate in the U.S., and launching Healthy Edge, a pack combining Protandim Nrf2 Synergizer and the P84 System. The company also expanded European sales to Iceland and Portugal, launched Petandim in Mexico, and introduced limited-edition AXIO Smart Energy flavors in the U.S. and Japan. CEO Terrence Moorehead cited differentiated science-backed products, strong gross margins and a debt-free balance sheet as the foundation for the plan.

Risks

• Independent consultant retention and motivation — The company has faced challenges motivating and incentivizing independent consultants and has experienced discord among leading consultants, which the 10-K states could cause loss of leaders to competing direct selling companies and a significant negative impact on revenue.
• Revenue concentration in a few products — The 10-K lists dependence upon a few products for revenue as a risk factor for a business whose flagship line remains Protandim.
• Regulatory and direct-selling compliance — The company notes risk that its direct selling program could be found non-compliant with current or newly adopted laws, plus risks of investigatory and enforcement action and laws restricting direct selling in various markets.
• Nasdaq listing and stock price — Risk factors include potential delisting of common stock for non-compliance with Nasdaq continued listing requirements and volatility in the market price of the common stock.

Outlook

Management describes recent results as challenging but expresses optimism, citing a differentiated science-backed platform, strong gross margins and a debt-free balance sheet. The company says it will move with urgency on brand strengthening, a more relevant consumer proposition and operational excellence, and will share more on strategy as work progresses. No specific financial guidance figures were provided in the earnings release excerpt.